CEX Capital Invests in Spanish Pharma Firm Plusquam Pharma

CEX Capital has acquired a 25% stake in Plusquam Pharma, a Spanish pharmaceutical company focused on dietary supplements and health products. This strategic investment aims to fuel the growth of the Extremadura-based firm, which operates in the consumer health and pharmaceutical sectors. The deal underscores CEX Capital's commitment to supporting innovative companies within the region.

Plusquam Pharma specializes in four key product areas: urological health, comprehensive women's health, digestive probiotics, and functional oral rehydration. Its established brands, including UROCRAN, ACTIFEMME, VITAPLUS, and HIDRASAL, have carved out significant market positions, with UROCRAN recognized as a national leader in its category. The company's foundation in 2011 by experienced pharmaceutical professionals has positioned it for expansion.

The investment from CEX Capital is earmarked for accelerating Plusquam Pharma's expansion through enhanced commercial networks, targeted marketing initiatives, and robust research and development. This infusion of capital is expected to broaden the company's product portfolio and solidify its market presence. Eduardo Rodríguez Quirós, Investment Director at CEX Capital, highlighted Plusquam Pharma's innovative approach and specialized knowledge as key drivers for the investment.

The pharmaceutical and health sector represents a critical area for regional economic development, offering opportunities for skilled job creation and high-value business activity. Quirós emphasized that CEX Capital actively seeks to partner with enterprises demonstrating strong growth potential and a commitment to innovation, particularly those based in Extremadura. This aligns with the corporation's strategy of providing strategic support to companies poised for significant advancement.

María Romero, CEO of Plusquam Pharma, expressed enthusiasm for the partnership, viewing CEX Capital's involvement as a significant endorsement of the company's sustainable growth model. She noted a shared long-term vision that will empower Plusquam Pharma to enhance its commercial capabilities and innovation efforts, ultimately leading to the development of more solutions aimed at improving quality of life. The company's dedication to R&D, driven by a multidisciplinary team of pharmacists, mathematicians, and physicians, is a cornerstone of its strategy.

This collaboration signifies a strategic move within the European pharmaceutical and health supplement market, a sector that has seen consistent growth driven by increasing consumer focus on wellness and preventative health. The Spanish market, in particular, benefits from a strong base of pharmaceutical innovation and a growing demand for specialized health products. CEX Capital's investment in Plusquam Pharma is a testament to the region's potential in this dynamic industry.